CASI Pharmaceuticals, Inc.
New Form D on file · 2026-04-28 · the record
What the record says
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 148 filings in Pharmaceuticals, totalled by week. The dot is this raise, $5M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Company officers on record
On the filing as: Director.
Wei-Wu He is named as Chairman to the Board on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
Zhenbo Su is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
Thomas Folinsbee is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
Alexander Wu is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
Xuebo Zeng is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Wei Gao is named as General Counsel on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Kun Qian is named as Global Controller on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Chunhua Wang is named as Chief Operating Officer on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Hai Huang is named as Global Chief Commercial Officer on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
On the filing as: Executive Officer.
Wei (Larry) Zhang is named as Vice President on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
James Huang is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
Barbara Krebs-Pohl is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 April 2026, one of 12 people that filing names.
12 people named on the filing — 5 holding an executive role and 7 as directors only.
Named as of the 2026-04-28 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 12 people named on the filing — 5 holding an executive role and 7 as directors only.
No investor is drawn from a Form D — the form states how many invested and never who.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on CASI Pharmaceuticals, Inc.
- Source Check — verify Wei-Wu He's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Wei-Wu He for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist CASI Pharmaceuticals, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind CASI Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.